(Q54439772)

English

An integrated multiple-analyte pharmacokinetic model to characterize trastuzumab emtansine (T-DM1) clearance pathways and to evaluate reduced pharmacokinetic sampling in patients with HER2-positive metastatic breast cancer.

scientific article published in August 2013

In more languages

default for all languages

No label defined

No description defined

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

29 May 2018

http://europepmc.org/abstract/MED/23553425

An integrated multiple-analyte pharmacokinetic model to characterize trastuzumab emtansine (T-DM1) clearance pathways and to evaluate reduced pharmacokinetic sampling in patients with HER2-positive metastatic breast cancer. (English)

1 reference

Europe PubMed Central

PubMed publication ID

29 May 2018

http://europepmc.org/abstract/MED/23553425

1 reference

based on heuristic

inferred from title

pharmacokinetics

1 reference

based on heuristic

inferred from title

author name string

Dan Lu

1

1 reference

Europe PubMed Central

PubMed publication ID

29 May 2018

http://europepmc.org/abstract/MED/23553425

Amita Joshi

2

1 reference

Europe PubMed Central

PubMed publication ID

29 May 2018

http://europepmc.org/abstract/MED/23553425

Bei Wang

3

1 reference

Europe PubMed Central

PubMed publication ID

29 May 2018

http://europepmc.org/abstract/MED/23553425

Steve Olsen

4

1 reference

Europe PubMed Central

PubMed publication ID

29 May 2018

http://europepmc.org/abstract/MED/23553425

Joo-Hee Yi

5

1 reference

Europe PubMed Central

PubMed publication ID

29 May 2018

http://europepmc.org/abstract/MED/23553425

Ian E Krop

6

1 reference

Europe PubMed Central

PubMed publication ID

29 May 2018

http://europepmc.org/abstract/MED/23553425

Howard A Burris

7

1 reference

Europe PubMed Central

PubMed publication ID

29 May 2018

http://europepmc.org/abstract/MED/23553425

Sandhya Girish

8

1 reference

Europe PubMed Central

PubMed publication ID

29 May 2018

http://europepmc.org/abstract/MED/23553425

publication date

1 August 2013

1 reference

Europe PubMed Central

PubMed publication ID

29 May 2018

http://europepmc.org/abstract/MED/23553425

Clinical Pharmacokinetics

1 reference

Europe PubMed Central

PubMed publication ID

29 May 2018

http://europepmc.org/abstract/MED/23553425

52

1 reference

Europe PubMed Central

PubMed publication ID

29 May 2018

http://europepmc.org/abstract/MED/23553425

8

1 reference

Europe PubMed Central

PubMed publication ID

29 May 2018

http://europepmc.org/abstract/MED/23553425

657-672

1 reference

Europe PubMed Central

PubMed publication ID

29 May 2018

http://europepmc.org/abstract/MED/23553425

Cancer statistics, 2012

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0060-Y

21 January 2018

The HER-2 receptor and breast cancer: ten years of targeted anti-HER-2 therapy and personalized medicine

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0060-Y

21 January 2018

Prognosis of women with metastatic breast cancer by HER2 status and trastuzumab treatment: an institutional-based review

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0060-Y

21 January 2018

Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0060-Y

21 January 2018

Prognostic significance of human epidermal growth factor receptor positivity for the development of brain metastasis after newly diagnosed breast cancer

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0060-Y

21 January 2018

Targeting HER2-positive breast cancer with trastuzumab-DM1, an antibody-cytotoxic drug conjugate

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0060-Y

21 January 2018

Trastuzumab-DM1 (T-DM1) retains all the mechanisms of action of trastuzumab and efficiently inhibits growth of lapatinib insensitive breast cancer

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0060-Y

21 January 2018

Trastuzumab-DM1 is highly effective in preclinical models of HER2-positive gastric cancer.

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0060-Y

21 January 2018

Phase II study of the antibody drug conjugate trastuzumab-DM1 for the treatment of human epidermal growth factor receptor 2 (HER2)-positive breast cancer after prior HER2-directed therapy

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0060-Y

21 January 2018

A phase II study of trastuzumab emtansine in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer who were previously treated with trastuzumab, lapatinib, an anthracycline, a taxane, and capecitabine

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0060-Y

21 January 2018

Phase II randomized study of trastuzumab emtansine versus trastuzumab plus docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0060-Y

21 January 2018

Trastuzumab emtansine for HER2-positive advanced breast cancer

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0060-Y

21 January 2018

Clinical pharmacology of trastuzumab emtansine (T-DM1): an antibody-drug conjugate in development for the treatment of HER2-positive cancer

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0060-Y

21 January 2018

Phase I study of trastuzumab-DM1, an HER2 antibody-drug conjugate, given every 3 weeks to patients with HER2-positive metastatic breast cancer

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0060-Y

21 January 2018

Conditional weighted residuals (CWRES): a model diagnostic for the FOCE method.

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0060-Y

21 January 2018

Diagnosing model diagnostics

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0060-Y

21 January 2018

Measuring the predictive performance of computer-controlled infusion pumps.

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0060-Y

21 January 2018

Importance of shrinkage in empirical bayes estimates for diagnostics: problems and solutions

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0060-Y

21 January 2018

Tumor delivery and in vivo processing of disulfide-linked and thioether-linked antibody-maytansinoid conjugates

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0060-Y

21 January 2018

Conjugation site modulates the in vivo stability and therapeutic activity of antibody-drug conjugates.

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0060-Y

21 January 2018

Pharmacokinetics and biodistribution of the antitumor immunoconjugate, cantuzumab mertansine (huC242-DM1), and its two components in mice

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0060-Y

21 January 2018

Clinical pharmacokinetics of bevacizumab in patients with solid tumors.

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0060-Y

21 January 2018

Rationale for fixed dosing of pertuzumab in cancer patients based on population pharmacokinetic analysis

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0060-Y

21 January 2018

Antibody pharmacokinetics and pharmacodynamics

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0060-Y

21 January 2018

In search of physiologically based distribution volume estimates for macromolecules

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0060-Y

21 January 2018

Semi-mechanistic population pharmacokinetic model of multivalent trastuzumab emtansine in patients with metastatic breast cancer

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0060-Y

21 January 2018

Population pharmacokinetics of trastuzumab in patients with HER2+ metastatic breast cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/23553425

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Clinical significance of HER-2/neu oncogene amplification in primary breast cancer. The South Australian Breast Cancer Study Group

1 reference

https://pubmed.ncbi.nlm.nih.gov/23553425

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Population pharmacokinetics of rituximab in patients with chronic lymphocytic leukemia

1 reference

https://pubmed.ncbi.nlm.nih.gov/23553425

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Effects of Trastuzumab Emtansine (T-DM1) on QT Interval and Safety of Pertuzumab Plus T-DM1 in Patients With Previously Treated Human Epidermal Growth Factor Receptor 2-Positive Metastatic Breast Cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/23553425

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Clinical implications of pathophysiological and demographic covariates on the population pharmacokinetics of trastuzumab emtansine, a HER2-targeted antibody-drug conjugate, in patients with HER2-positive metastatic breast cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/23553425

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

The prospective use of population pharmacokinetics in a computer-driven infusion system for alfentanil.

1 reference

https://pubmed.ncbi.nlm.nih.gov/23553425

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Prognostic and predictive value of c-erbB-2 overexpression in primary breast cancer, alone and in combination with other prognostic markers

1 reference

https://pubmed.ncbi.nlm.nih.gov/23553425

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1007/S40262-013-0060-Y

1 reference

Europe PubMed Central

PubMed publication ID

29 May 2018

http://europepmc.org/abstract/MED/23553425

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

29 May 2018

http://europepmc.org/abstract/MED/23553425

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q54439772&oldid=2212468008"